Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin on Postprandial Lipids in Type 2 Diabetes
NCT00099957Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2003
- Primary completion
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Vildagliptin Arm with Placebo Arm (2 arms). Primary endpoint: Postprandial serum total triglycerides at 4 weeks. Started Sep 2003; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00099957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099957.